23andMe IPO

23andme.com

23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.

23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.

Founded2006
Total Funding to Date$876.61MM
Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

23andMe Ticker Symbol

23andMe does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

23andMe Stock Price

The stock price for 23andMe will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for 23andMe

Fidelity Investments
Casdin Capital
Altimeter Capital
Sequoia Capital

23andMe Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
12/23/2020 Series F-1 $2.59B $XXX.XX $XXX.XX
9/12/2017 Series F $1.75B $XXX.XX $XXX.XX
6/8/2015 Series E $1.1B $XXX.XX $XXX.XX
12/10/2012 Series D $288.74MM $XXX.XX $XXX.XX
11/10/2010 Series C $184.5MM $XXX.XX $XXX.XX
12/23/2009 Series B $150.5MM $XXX.XX $XXX.XX
5/22/2007 Series A $48.5MM $XXX.XX $XXX.XX
Based on primary financings

Other companies like 23andMe in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM